The TGA has published transition
arrangements for the reform of
its Orphan Drug Program, which is
undergoing its first review in almost
two decades.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 02 May 17 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 May 17
CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).